AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2011-10-06
Target enrollment:
Participant gender:
Summary
Background:
- AZD2171 is an experimental drug that may slow the growth of cancers by blocking
angiogenesis (formation of new blood vessels).
- Cancer growth is dependent on angiogenesis for nutrition.
- Inhibiting angiogenesis is a new approach to cancer therapy.
Objectives:
- To determine the side effects of AZD2171 in children and adolescents with cancer.
- To determine the highest dose of AZD2171 that can safely be given to children and
adolescents with cancer.
- To study how the body handles AZD2171.
- To determine the effects of AZD2171 on various factors related to angiogenesis.
- To determine if AZD2171 can inhibit cancer growth in children and adolescents.
Eligibility:
-Children and adolescents 2-18 years of age with treatment-resistant solid tumor cancers or
acute myelogenous leukemia.
Design:
- About 40 patients may be included in the study.
- AZD2171 is given by mouth in treatment cycles of once a day for 28 days. Treatment may
continue unless the cancer worsens or unacceptable side effects develop.
- Patients have periodic physical examinations, blood and urine tests and imaging tests
(CT, X-rays, MRI) to evaluate disease throughout the course of treatment. Additional
blood tests are done to study how the body handles AZD2171, to look for proteins that
stimulate angiogenesis, to determine if certain blood vessel cells are affected by
AZD2171, and for other research purposes.
- Biopsy tissue (when available) is examined for the receptor for new blood vessel
formation.